

Oregon Cardiovascular Symposium

All Sessions will be Posted Online on Friday Morning and Available for Viewing in the Order of Your Choosing

4 Minutes	Introduction Recording – Please Watch First
LIVE SESSION at 9:00 AM – Saturday and Recorded for Follow Up Viewing	<p>Session #1 - Independent CME Activity: Mastering the Art of Prior Authorization to Improve Patient Access to PCSK9 Inhibitors — Integrity Continuing Education <i>James Underberg, MS, MD, FACPM, FACP, FNLA, NYU Langone Health</i> https://virtual.arraylearn.com/activity_files/f57e5e74-7e68-11ea-b7b3-005056011b62/04182020_PCSK9.html</p>
LIVE SESSION at 10:30 AM – Saturday and Recorded for Follow Up Viewing	<p>Session #2 - Independent CME Activity — Redefining the Role of Cardiologists in the Management of Type 2 Diabetes: Best Practices for Cardiovascular Risk Reduction — Integrity Continuing Education <i>Silvio Inzucchi, MD, Yale School of Medicine</i> https://virtual.arraylearn.com/activity_files/d4b77c56-7e8a-11ea-b7b3-005056011b62/04182020_T2DM.html</p>
1 Hour	<p>Session #3 - Independent CME Activity — Dual Antiplatelet Therapy in Coronary Artery Disease: New Guidelines and Beyond — Rockpointe CME <i>L. Kristin Newby, MD, MHS, Duke University</i></p>
1 Hour	<p>Session #4 — Keto, Paleo, Fasting — Oh My? Navigating the Evidence for a Cardioprotective Diet <i>Tracy Severson, RD, LD, OHSU</i></p>
1 Hour	<p>Session #5 — Shared Decision Making in the Treatment of Cardiac Disease <i>Dan Matlock, MD, MPH, University of Colorado</i></p>
1 Hour	<p>Session #6 — High Sensitivity Troponin, Type 2 MI, and the Everchanging Definition of Myocardial Infarctions <i>James de Lemos, MD, PhD, UT Southwestern</i></p>
1 Hour	<p>Session #7 — Intersection of Antiplatelet and Anticoagulant Therapy — How to Best Manage Patients Who Need Both? <i>L. Kristin Newby, MD, MHS, Duke University</i></p>
1 Hour	<p>Session #8 — Novel Strategies Screening for CVD — Genetics, Biomarkers, Imaging, etc. <i>James de Lemos, MD, PhD, UT Southwestern</i></p>
1 Hour	<p>Session #9 — The Tricuspid Valve — Current Therapies and Updates on Tricuspid Valve Management <i>Vinod Thourani, MD, FACS, FACC, Piedmont Heart Institute</i></p>
1 Hour	<p>Session #10 — Role of Biomarkers and Imaging in CVD Prevention <i>Michael Shapiro, DO, FACC, Wake Forest University</i></p>
1 Hour	<p>Session #11 — Low and Moderate Risk Severe Aortic Stenosis — How to Develop a 20 - 30 Year Plan — TAVR, SAVR, and Valve in Valve Treatment Strategies <i>Vinod Thourani, MD, FACS, FACC, Piedmont Heart Institute</i></p>
1 Hour	<p>Session #12 — Advanced Heart Failure — When to Refer for Advanced Therapies and When to Refer to Hospice <i>James Fang, MD, University of Utah</i></p>
1 Hour	<p>Session #13 – Cardiovascular Complications of COVID-19 and Roundtable Discussion <i>Ty Gluckman, MD, FACC, Providence Heart and Vascular</i></p>
1 Hour	<p>Session #14 — Top 10 Clinical Pearls in Treating Heart Failure <i>James Fang, MD, University of Utah</i></p>
1 Hour	<p>Session #15 — Surgical and Interventional Left Atrial Appendage Closure — Are We Sure This is Beneficial? <i>Matthew Brennan, MD, MPH, Duke University</i></p>
1 Hour	<p>Session #16 — Hypertension Guidelines — Debating the Goals <i>Matthew Sorrentino, MD, FACC, FAHA, University of Chicago</i></p>
1 Hour	<p>Session #17 — Combining Anatomic and Functional Information in the Assessment of CAD — Coronary CTA with Fractional Flow Reserve <i>Maros Ferencik, MD, PhD, OHSU</i></p>